Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

被引：0
|
作者：
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
机构：
[1] Sarah Cannon Research Institute and the Tennessee Oncology,Department of Surgery, Oncology and Gastroenterology
[2] PLLC,undefined
[3] University of Pittsburgh Medical Center,undefined
[4] Weston Park Hospital,undefined
[5] Sheffield Cancer Research Center,undefined
[6] University of Padova,undefined
[7] Padova,undefined
[8] and Istituto Oncologico Veneto IRCCS,undefined
[9] Vall d’Hebron Institute of Oncology (VHIO),undefined
[10] Celgene Corporation,undefined
[11] Centre de Lutte Contre le Cancer d’Auvergne,undefined
[12] Texas Oncology-Baylor Charles A. Sammons Center; US Oncology,undefined
[13] Breast Center,undefined
[14] University of Munich,undefined
来源：
Trials | / 17卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pierfranco F.
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Mark A.
    O'Shaughnessy, Joyce
    Beck, Robert M.
    Ko, Amy
    Renschler, Markus F.
    Barton, Debora
    Harbeck, Nadia
    TRIALS, 2015, 16
  • [2] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    Denise A. Yardley
    Adam Brufsky
    Robert E. Coleman
    Pierfranco F. Conte
    Javier Cortes
    Stefan Glück
    Jean-Mark A. Nabholtz
    Joyce O’Shaughnessy
    Robert M. Beck
    Amy Ko
    Markus F. Renschler
    Debora Barton
    Nadia Harbeck
    Trials, 16
  • [3] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015)
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pierfranco F.
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Mark A.
    O'Shaughnessy, Joyce
    Beck, Robert M.
    Ko, Amy
    Renschler, Markus F.
    Barton, Debora
    Harbeck, Nadia
    TRIALS, 2016, 17
  • [4] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
    Yardley, D. A.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    de la Cruz-Merino, L.
    Wilks, S.
    O'Shaughnessy, J.
    Gluck, S.
    Li, H.
    Miller, J.
    Barton, D.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
  • [5] tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer
    Yardley, D. A.
    Brufsky, A.
    Conte, P.
    Cortes, J.
    Glueck, S.
    Nabholtz, J-Ma
    O'Shaughnessy, J.
    Li, L.
    Barton, D.
    Fandi, A.
    Harbeck, N.
    CANCER RESEARCH, 2013, 73
  • [6] nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial
    Yardley, D.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    Merino, L. de la Cruz
    Wilks, S.
    O'Shaugnessy, J.
    Gluck, S.
    Li, H.
    Beck, R.
    Barton, D.
    Harbeck, N.
    CANCER RESEARCH, 2017, 77
  • [7] tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pier Franco
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Marc A.
    O'Shaughnessy, Joyce
    Li, Li
    Barton, Debora
    Beck, Robert M.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
    O'Shaughnessy, Joyce
    Schwartzberg, Lee
    Danso, Michael A.
    Miller, Kathy D.
    Rugo, Hope S.
    Neubauer, Marcus
    Robert, Nicholas
    Hellerstedt, Beth
    Saleh, Mansoor
    Richards, Paul
    Specht, Jennifer M.
    Yardley, Denise A.
    Carlson, Robert W.
    Finn, Richard S.
    Charpentier, Eric
    Garcia-Ribas, Ignacio
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) : 3840 - U232
  • [9] tnAcity: A phase II/III trial of nab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)
    Yardley, Denise A.
    Coleman, Robert E.
    Conte, Pierfranco
    O'Shaughnessy, Joyce
    Cortes, Javier
    Glueck, Stefan
    Brufsky, Adam
    Nabholtz, Jean-Marc A.
    Li, Li
    Miller, JulieAnn
    Barton, Debora
    Harbeck, Nadia
    CANCER RESEARCH, 2015, 75
  • [10] Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
    Yardley, Denise A.
    Cortes, Javier
    Coleman, Robert E.
    Conte, Pier Franco
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Wright, Gail Lynn Shaw
    Eakle, Janice F.
    Wilks, Sharon
    Shtivelband, Mikhail
    Young, Robyn R.
    Bengala, Carmelo
    Li, Huiling
    Miller, Julie Ann
    Barton, Debora
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345